PFM Health Sciences, LP reported 95 positions worth $1.14B for the quarter ended Jun 30, 2026, up 28.4% on the prior quarter. It opened 32 new positions, added to 22, trimmed 41 and exited 9. Its largest holding is Ascendis Pharma A/S at 5.4% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| HUM Humana Inc | +94.4K | – | $37.49M | 3.28% |
| ASND Ascendis Pharma A/S | +81.1K | +53.4% | $21.64M | 5.44% |
| MTD Mettler Toledo International Inc/ | +13.3K | – | $17.05M | 1.49% |
| MRK Merck & Co., Inc. | +127.1K | – | $16.33M | 1.43% |
| CYTK Cytokinetics Inc | +191.7K | – | $16.33M | 1.43% |
| LNTH Lantheus Holdings, Inc. | +146.4K | – | $16.24M | 1.42% |
| CVS CVS HEALTH Corp | +137.5K | – | $14.22M | 1.24% |
| ICLR Icon Plc | +79.0K | +137.4% | $13.72M | 2.07% |
| UNH Unitedhealth Group Inc | +30.2K | +52.1% | $12.57M | 3.21% |
| GILD Gilead Sciences, Inc. | +90.9K | – | $11.48M | 1% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| THC Tenet Healthcare Corp | -272.0K | -68.2% | $50.88M | 2.07% |
| LLY ELI LILLY & Co | -26.5K | -40.3% | $31.79M | 4.12% |
| PEN Penumbra Inc | -79.6K | -56.9% | $25.12M | 1.66% |
| GKOS GLAUKOS Corp | -215.7K | -100.0% | $23.22M | Exited |
| CMPS COMPASS Pathways plc | -1.12M | -81.9% | $15.84M | 0.306% |
| NEO Neogenomics Inc | -1.78M | -100.0% | $13.24M | Exited |
| AXSM Axsome Therapeutics, Inc. | -44.7K | -16.9% | $10.94M | 4.7% |
| NTRA Natera, Inc. | -37.9K | -63.2% | $10.30M | 0.524% |
| DXCM Dexcom Inc | -149.7K | -100.0% | $9.40M | Exited |
| AMRX Amneal Pharmaceuticals, Inc. | -449.4K | -48.3% | $7.78M | 0.727% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| HUM Humana Inc | +94.4K | $37.49M | 3.28% |
| MTD Mettler Toledo International Inc/ | +13.3K | $17.05M | 1.49% |
| MRK Merck & Co., Inc. | +127.1K | $16.33M | 1.43% |
| CYTK Cytokinetics Inc | +191.7K | $16.33M | 1.43% |
| LNTH Lantheus Holdings, Inc. | +146.4K | $16.24M | 1.42% |
| CVS CVS HEALTH Corp | +137.5K | $14.22M | 1.24% |
| GILD Gilead Sciences, Inc. | +90.9K | $11.48M | 1% |
| TFX Teleflex Inc | +79.7K | $10.10M | 0.883% |
| IRTC iRhythm Holdings, Inc. | +65.2K | $7.76M | 0.678% |
| WST West Pharmaceutical Services Inc | +20.7K | $7.44M | 0.651% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| GKOS GLAUKOS Corp | -215.7K | $23.22M | 2.61% |
| NEO Neogenomics Inc | -1.78M | $13.24M | 1.49% |
| DXCM Dexcom Inc | -149.7K | $9.40M | 1.06% |
| BLLN BillionToOne, Inc. | -88.1K | $6.95M | 0.78% |
| CAH Cardinal Health Inc | -31.9K | $6.75M | 0.758% |
| ALHC Alignment Healthcare, Inc. | -359.8K | $6.34M | 0.712% |
| PSNL Personalis, Inc. | -870.1K | $5.54M | 0.622% |
| MDLN Medline Inc. | -86.8K | $3.86M | 0.433% |
| GMED Globus Medical Inc | -16.9K | $1.46M | 0.164% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASND Ascendis Pharma A/S | Healthcare | 233.2K | $62.19M | 5.44% | +81.1K | +53.4% | Added | 0.38% |
| 2 | AXSM Axsome Therapeutics, Inc. | Healthcare | 219.6K | $53.75M | 4.7% | -44.7K | -16.9% | Reduced | 0.42% |
| 3 | LLY ELI LILLY & Co | Healthcare | 39.3K | $47.09M | 4.12% | -26.5K | -40.3% | Reduced | 0% |
| 4 | JAZZ Jazz Pharmaceuticals plc | Healthcare | 160.8K | $38.74M | 3.39% | -17.4K | -9.8% | Reduced | 0.25% |
| 5 | HUM Humana Inc | Healthcare | 94.4K | $37.49M | 3.28% | +94.4K | – | New | 0.08% |
| 6 | UNH Unitedhealth Group Inc | Healthcare | 88.3K | $36.69M | 3.21% | +30.2K | +52.1% | Added | 0.01% |
| 7 | NBIX Neurocrine Biosciences Inc | Healthcare | 213.4K | $35.97M | 3.14% | -2,271 | -1.1% | Reduced | 0.21% |
| 8 | INBX Inhibrx Biosciences, Inc. | Healthcare | 308.4K | $29.22M | 2.55% | +2,954 | +1.0% | Added | 1.97% |
| 9 | UTHR UNITED THERAPEUTICS Corp | Healthcare | 50.0K | $27.09M | 2.37% | +10.2K | +25.6% | Added | 0.12% |
| 10 | RVMD Revolution Medicines, Inc. | Healthcare | 143.2K | $26.82M | 2.34% | +2,452 | +1.7% | Added | 0.07% |
| 11 | ICLR Icon Plc | Healthcare | 136.5K | $23.71M | 2.07% | +79.0K | +137.4% | Added | 0.17% |
| 12 | THC Tenet Healthcare Corp | Healthcare | 126.6K | $23.68M | 2.07% | -272.0K | -68.2% | Reduced | 0.15% |
| 13 | EW Edwards Lifesciences Corp | Healthcare | 250.5K | $22.66M | 1.98% | -4,057 | -1.6% | Reduced | 0.04% |
| 14 | WAT Waters Corp | Healthcare | 59.8K | $22.44M | 1.96% | +20.1K | +50.5% | Added | 0.06% |
| 15 | PEN Penumbra Inc | Healthcare | 60.2K | $19.01M | 1.66% | -79.6K | -56.9% | Reduced | 0.15% |
Tip. Select a row to see that position’s full history at PFM Health Sciences.
As of its Q2 2026 13F filing, PFM Health Sciences, LP’s five largest positions were Ascendis Pharma A/S (ASND) at 5.4%, Axsome Therapeutics, Inc. (AXSM) at 4.7%, ELI LILLY & Co (LLY) at 4.1%, Jazz Pharmaceuticals plc (JAZZ) at 3.4%, Humana Inc (HUM) at 3.3% of the reported portfolio.
PFM Health Sciences, LP reported a 13F portfolio worth $1.14B across 95 positions for Q2 2026. That is up 28.4% from the previous quarter.
Its largest purchases by value were Humana Inc ($37.49M), Ascendis Pharma A/S ($21.64M), Mettler Toledo International Inc/ ($17.05M). It opened 32 new positions.
Its largest sales by value were Tenet Healthcare Corp ($50.88M), ELI LILLY & Co ($31.79M), Penumbra Inc ($25.12M). It exited 9 positions entirely.
From the Form 13F-HR reports PFM Health Sciences, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.